Physician profile
Sohail Bazel
NPI 1225003353
$3,619.23
in general payments reported to CMS, 2019-2025
31 companies · $833 in 2025
The $833 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.03 · 2021: $263 · 2022: $687 · 2023: $925 · 2024: $896 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $986.28 | 2022-2025 | Ubrelvy, Linzess |
| Lilly USA, LLC | $501.30 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Welch Allyn | $263.41 | 2021 | |
| Amgen INC. | $234.08 | 2022-2025 | Repatha, Otezla, Evenity |
| Collegium Pharmaceutical, INC. | $190.65 | 2023-2025 | Belbuca |
| Otsuka America Pharmaceutical, INC. | $189.43 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $137.01 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $128.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.42 | 2022-2025 | Relistor, Xifaxan, Trulance |
| Novo Nordisk INC | $106.36 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mylan Specialty L.P. | $102.16 | 2023-2024 | Yupelri |
| Forte Bio-Pharma LLC | $73.37 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.66 | 2022-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $53.03 | 2024 | |
| Gilead Sciences, INC. | $48.70 | 2023-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.72 | 2022 | |
| Glaxosmithkline, LLC. | $45.45 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Ardelyx, INC. | $43.71 | 2025 | Ibsrela |
| Eisai INC. | $37.55 | 2023 | |
| Idorsia Pharmaceuticals US INC | $36.10 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.85 | 2025 | Caplyta |
| Corcept Therapeutics | $26.88 | 2025 | Korlym |
| Biogen, INC. | $23.25 | 2024 | Qalsody, Spinraza |
| Phadia US INC. | $18.95 | 2022 | |
| Edwards Lifesciences Corporation | $17.85 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shield Therapeutics INC | $15.12 | 2023 | Accrufer |
| Exact Sciences Corporation | $14.19 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $13.61 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.03 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $12.44 | 2022 | |
| Inogen, INC. | $10.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Bazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.